Research in recent decades has been focused on understanding the phenomenon of multidrug resistance (MDR) in cancer cells (Nooter and Stoter, 1996
In other studies, GLP-1RA addition did not increase the risk of hypoglycemia
In animal studies, AOD-9604 reduced body weight gain by over 50% in obese mice during a 19-day treatment period, and significantly increased fat oxidation all without affecting insulin sensitivity or glucose regulation.[1,3] A randomized controlled trial in humans found that participants taking 1 mg of AOD-9604 daily lost an average of 2.8 kg (~6 lbs) over 23 weeks, compared to 0.8 kg (~1.7 lbs) in the placebo group
This makes its systemic presence very transient
This product is not intended for: Human consumption Medical treatment Disease diagnosis Disease prevention Veterinary applications Therapeutic use Purchasers are responsible for ensuring compliance with all applicable laws, regulations, and institutional requirements regarding the acquisition, handling, storage, and use of research peptides
